#United States #Washington D.C. #MetaVia #Vanoglipel #Phase 2a Data

MetaVia Presents Promising Phase 2a Data on Vanoglipel (DA-1241)

At the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, MetaVia Inc. released remarkable results from its Phase 2a clinical trial evaluating vanoglipel (DA-1241), a potent and selective G protein-coupled receptor 119 (GPR119) agonist.

Overview of the Study

This randomized, placebo-controlled trial involved 109 subjects suffering from presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH). The study assessed vanoglipel both as a standalone therapy and in conjunction with a dipeptidyl peptidase-4 inhibitor (DPP4i) to enhance the effects of endogenous GLP-1. The treatment periods lasted 16 weeks, scrutinizing metrics such as glucose regulation, liver health, and plasma lipid profiles.

Key Findings

The trial showcased clinically significant reductions in HbA1c levels, marking essential advances in glucose control. Notably, improvements were documented from the fourth week of the treatment. At the conclusion of the study, mean HbA1c levels showed a decrease of –0.54% with vanoglipel alone and –0.66% in combination with DPP4i, emphasizing its effectiveness beyond conventional weight loss therapies.

Furthermore, vanoglipel exhibited impressive potential in ameliorating liver concerns, including inflammation and fibrosis. The treatment resulted in a noticeable decline in plasma ALT levels and showcased enhancements in liver steatosis measured through various imaging techniques.

Mechanism of Action

Vanoglipel works by stimulating GPR119, which triggers the release of vital gut peptides crucial for glucose metabolism, lipid regulation, and overall weight management. The successful outcomes observed could position vanoglipel as a game-changer in MASH treatments, displaying both hepatic and metabolic benefits through its unique oral administration.

Conclusion of Findings

In summary, the positive results from MetaVia's trial not only signify vanoglipel's effectiveness as a therapeutic option for MASH but also affirm its role in addressing the broader spectrum of cardiometabolic diseases. With continued development, vanoglipel holds the potential to influence treatment outcomes significantly for patients suffering from related metabolic disorders. As the data resonate through the medical community, vanoglipel's dual-action approach could herald a new phase in the management of complex liver conditions associated with metabolic dysfunction.

Looking Ahead

The findings were presented in a dedicated poster session at the AASLD meeting by Dr. Rohit Loomba, a reputable figure in gastroenterology and hepatology. As the healthcare sector keenly anticipates further research, the implications of these results may pave the way for innovative therapeutic approaches targeting multifaceted health concerns rooted in metabolic dysfunction.